Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO Presentation - Verastem (NAS

Verastem Oncology Inc (NASDAQ:VSTM) stock is trading higher after updated data from the ongoing Phase 1/2 FRAME study.
The investigator-sponsored study is investigating VS-6766, Verastem's RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low-grade serous ovarian cancer (LGSOC).
Related Link: Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock.
The findings were presented at the European Society of Medical Oncology (ESMO21) Congress 2021.
In the study, the median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib is 23.0 months.
11 of 24 (46%) patients treated with the combination achieved a confirmed partial response (PR).
Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.
The Company said that for other therapies studied in recurrent LGSOC, response rates have been between 6% and 26%, and mPFS was between 7.2 and 13.0 months.
As of the April data cutoff date, 13 of 24 patients (54%) remained on study.
Verastem's Company-sponsored, registration-directed Phase 2 RAMP 201 study evaluating VS-6766 both alone and in combination with defactinib in patients with recurrent LGSOC is ongoing.
The Company plans to report top-line results from the selection portion of the study in 1H of 2022.
Price Action: VSTM shares are up 30.4% at $3.60 during the premarket session on the last check Monday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

VSTMVerastem Inc

$3.98-0.38%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.